Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.67 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.55 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3285916 | 1.00 | FLT3 (0.73) | FLT3LRRK2MDM2PDGFRBRPS6KA3 | |
| SCHEMBL3285165 | 1.00 | FLT3 (0.73) | FLT3LRRK2MDM2PDGFRBRPS6KA3 | |
| SCHEMBL3290705 | 0.88 | FLT3 (0.79) | FLT3LRRK2MDM2RPS6KA3RAF1 | |
| SCHEMBL3283768 | 0.88 | FLT3 (0.79) | FLT3LRRK2MDM2RPS6KA3RAF1 | |
| SCHEMBL3283766 | 0.88 | FLT3 (0.79) | FLT3LRRK2MDM2RPS6KA3RAF1 | |
| SCHEMBL3284018 | 0.85 | FLT3 (1.00) | FLT3LRRK2MDM2PDGFRBRPS6KA3 | |
| SCHEMBL3285276 | 0.85 | FLT3 (1.00) | FLT3LRRK2MDM2PDGFRBRPS6KA3 | |
| SCHEMBL3284013 | 0.85 | FLT3 (1.00) | FLT3LRRK2MDM2PDGFRBRPS6KA3 | |
| SCHEMBL3284988 | 0.85 | FLT3 (0.73) | FLT3LRRK2MDM2PDGFRBRPS6KA3 | |
| SCHEMBL13359321 | 0.85 | FLT3 (0.73) | FLT3LRRK2MDM2RPS6KA3RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918277-B1 | Azulene compounds | IND TECH RES INST (TW) | 2015-06-10 | — | — | EP | disclosed |
| US-7714146-B2 | Azulene-oxindole compounds as multiple-kinase inhibitors and useful as anticancer agents | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2010-05-11 | — | — | US | disclosed |
| US-20080125590-A1 | Azulene compounds | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2008-05-29 | — | — | US | disclosed |
| EP-1918277-A2 | Azulene compounds | Industrial Technology Research Institute (TW) | 2008-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125590-A1 | Azulene compounds | AZI2, PRMT5, BRCA1 | FLT3 796/4885LRRK2 1455/4885MDM2 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.